Sep 08, 2022 (ACCESSWIRE via COMTEX) -- TORONTO, ON / ACCESSWIRE / September 8, 2022 / Edesa Biotech, Inc. /zigman2/quotes/200172674/composite EDSA +3.62% , a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference being held in New York, NY on September 12-14, 2022.
Edesa Presentation Details
Date: September 12, 2022
Time: 10:00 am Eastern Time
Presentation Slides: Available in the events section of the Edesa website .
Attendees who are interested in meeting with the company should contact their H.C. Wainwright representative or Edesa directly via email at email@example.com .
About Edesa Biotech, Inc.
Edesa Biotech, Inc. /zigman2/quotes/200172674/composite EDSA +3.62% is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that Edesa is developing as a treatment for Acute Respiratory Distress Syndrome (ARDS). Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. Sign up for news alerts . Connect with Edesa Biotech on Twitter and LinkedIn .
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
SOURCE: Edesa Biotech
Is there a problem with this press release? Contact the source provider Comtex at firstname.lastname@example.org. You can also contact MarketWatch Customer Service via our Customer Center.